magic data fair valuationiniti perform
initi coverag madrig pharmaceut inc perform
rate price target base view compani uniqu
approach nash interest moa promis surrog data fair
rel valuat compani lead asset develop
nonalcohol steatohepat nash famili hypercholesterolemia fh
compani present posit surrog data nash easl next
near-term catalyst histolog data expect may believ histolog
show trend nash resolut fibrosi current fda approv endpoint
may suffici de-risk compound ahead drive substanti
upsid current stock price
oral -select thyroid hormon receptor agonist design
address dysregul lipid metabol compound advantag
clean safeti profil specif moa could make valuabl
combin estim total peak nash sale un-risk-adjust
risk-adjust estim total peak fh sale un-
risk-adjust risk-adjust
histolog readout focu near term predict histolog
show trend nash resolut fibrosi current approv endpoint
build base case outcom rel mild patient popul
smaller trial size outcom compound term magnitud
biomark improv subsequ histolog outcom
like initi program end expect
studi dose dose adjust week
treatment base biomark feedback believ enough cash
initi could rais cash seek non-dilut financ strength
result
ocaliva approv pbc fulli enrol nash trial market
cap demonstr improv nash endpoint larg derisk
safeti perspect gnft develop nash compound
demonstr nash resolut market cap
consid partial derisk term approv endpoint
nash resolut fibrosi improv potenti superior attribut
competitor limit upsid current level current assum
probabl success nash peak un-risk-adjust nash fh sale
compar consensu lead pt
madrig pharmaceut clinical-
pursu novel therapeut target
specif thyroid hormon pathway
liver common spectrum
cardio-metabol fatti liver diseas
high unmet medic need
analyst certif import disclosur see disclosur
surrog data on-going nash trial look promis
marker inflamm fibrosi show improv
surrog marker histolog data present
may
believ histolog show trend nash resolut
fibrosi approv endpoint
design trial base outcom
uniqu approach nash interest moa
promis surrog data high rel valuat
compani lead asset develop nash fh surrog
data on-going nash trial look promis marker
inflamm fibrosi show improv believ
histolog show signific improv na score point
due enrol popul trial size believ trial
show trend nash resolut fibrosi
may top line biopsi data nash trial
data hefh trial
pivot trial plan meet
initi nash
show signific resolut fibrosi improv
acquir
data fail show improv na score
unexpect safeti signal
price target base dcf valuat methodolog assum wacc residu growth rate
due patent expir model cash balanc million expect peak sale nash reach billion
ww us un-risk-adjust peak probabl success estim ww fh opportun reach un-risk-adjust sale
peak assum probabl success fh
key downsid risk price target clinic develop risk regulatori risk current phase trial
addit risk come lower expect peak sale due higher anticip competit failur gain support
medic commun healthcar prescrib third-parti payor risk relat legal challeng patent protect
product
upsid risk come better expect clinic data near-term histolog readout nash trial
initi coverag inc perform rate
price target base view compani uniqu approach nash
interest moa promis surrog data fair valuat
compani lead asset develop nonalcohol steatohepat nash
famili hypercholesterolemia fh oral activ small -select thyroid
hormon receptor agonist design address dysregul lipid metabol
one compound advantag clean safeti profil specif moa
could make valuabl combin therapi estim total peak nash sale
un-risk-adjust risk-adjust estim total peak fh
sale un-risk-adjust risk-adjust end
cash fund end accord estim
compani present posit surrog data nash easl near-term
focu histolog data may
surrog data on-going nash trial look promis marker
inflamm fibrosi show improv surrog marker
histolog data present may believ histolog show
signific improv na score point due enrol popul
trial size believ trial show trend nash resolut fibrosi
outlin base case outcom suffici continu develop
see compani current market cap fulli valu market
cap support demonstr improv na score fibrosi improv
nash trial conduct on-going fulli enrol trial nash sell
oca fda approv treatment pbc genfit gnft develop nash
compound demonstr nash resolut market cap
see yet suffici de-risk term approv endpoint
nash resolut fibrosi improv potenti superior attribut
competit warrant signific upsid level current assum
probabl success nash peak un-risk-adjust nash fh sale
compar consensu lead pt lower
price target base dcf valuat
methodolog assum wacc residu growth rate due
patent expir model cash balanc million
expect peak sale nash reach billion ww us un-
risk-adjust peak market share net annual price base
assum probabl success nash model us
row risk-adjust peak revenu nash assum
pay tier single-digit royalti roch fh built model preval
assum chronic use three popul sever hefh patient hefh
popul hefh patient ldl-c treatment goal hefh patient
hofh patient estim ww fh opportun reach un-risk-adjust
sale peak assum probabl success fh
key downsid risk price target clinic develop risk regulatori risk
current phase trial addit risk come lower expect
peak sale due higher anticip competit failur gain support
medic commun healthcar prescrib third-parti payor risk
relat legal challeng patent protect product
upsid risk come better expect clinic data near-term histolog
readout nash trial
exhibit catalyst calendar
data nash trial present easl
may top line biopsi data nash trial
top line data hefh trial
readout file hefh
readout file nash
launch hefh
launch nash
face sever major catalyst next month full data sever
top line result announc focu biopsi data may
sinc seen mri surrog biomark result thu far
histori stock price ownership
mdgl stock price ytd vs flat increas nbi
ownership predominantli hedg fund invest advisor mutual fund
insid own daili averag volum share current short interest
float day cover reverse-merg publicli trade synta
stock price increas upon posit top line decemb
littl reaction posit hefh top line februari stock
gain compar oct -nov prior poc data data on-going
toplin posit studi expect includ biopsi nash dataset
dsmb safeti
review nash
hefh
nash
enrol
preclin data
hefh
inc conshohocken pa-bas biopharmaceut
compani focus develop therapi liver diseas target thyroid
compani lead asset develop nonalcohol
steatohepat nash famili hypercholesterolemia fh oral
activ small molecul -select thyroid hormon receptor agonist design
address dysregul lipid metabol data suggest nash liver
defici thr- activ lead featur nash includ fatti liver
inflamm fibrosi thr- known regul cholesterol triglycerid
metabol could result
hypercholesterolemia genet dyslipidemia nash
therapeut benefit patient suffer
decemb
formerli known synta pharmaceut acquir
assum control develop
commerci hold exclus world-wide right potenti
indic roch exclus out-licens exchang up-front
payment mileston payment remaind total million tie
futur commenc clinic trial regulatori approv unit state
europ deriv product single-digit royalti payment
base net sale deriv product patent protect last
includ hatch-waxman extens
current develop nash patient famili
hypercholesterolemia data on-going toplin posit studi
expect expect potenti launch nash fh
expect peak sale nash reach billion ww us un-risk-
adjust peak market share annual price base
assum probabl success nash model us
row risk-adjust peak revenu nash assum pay
tier single-digit royalti roch fh built model preval assum
chronic use three popul sever hefh patient hefh popul
hefh patient ldl-c treatment goal hefh patient hofh
patient estim ww fh opportun reach un-risk-adjust sale
peak assum probabl success fh
end cash fund end accord
estim
exhibit sale estim segment
risk un-adjust ww salesrisk-adjust ww risk un-adjust sale per nash nash hefh hefh risk -adjust sale per nash nash hefh hefh un-adjust us nash nash hefh hefh adjust us nash nash hefh hefh row madrig pharmaceut inc
nonalcohol fatti liver diseas nafld nonalcohol steatohepat nash
caus liver diseas western countri nafld condit defin
excess fat accumul form triglycerid steatosi liver
hepatocyt histolog subgroup nafld patient liver cell injuri
inflamm addit excess fat steatohepat type nafl spectrum
condit design nash nash dramat increas risk cirrhosi liver
failur hepatocellular carcinoma nash wide consid liver
express metabol syndromediseas relat diabet mellitu type insulin
cholesterol hypertriglyceridemia hypertens exact progress diseas
understood especi multifactori caus accord two-
hit hypothesi first hit involv accumul tg hepatocyt caus
viciou cycl metabol dysfunct presenc hepat steatosi
establish progress steatohepat involv second hit oxid stress
exhibit progress nafld/nash
three underli activ use measur nash activ liver steatosi
inflamm hepatocyt balloon total na score repres sum score
steatosi lobular inflamm balloon rang accord
na prerequisit nash steatosi balloon discrimin factor
current approv endpoint nash fibrosi improv nash resolut
measur biopsi
exhibit score nash along clinic endpoint
patient typic asymptomat earli stage nafld diseas
suspect patient show elev level enzym alanine-transaminas alt
aspart transaminas ast non-invas techniqu mri
ultrasound ct use confirm steatosi transient elastographi fibroscan
detect fibrosi assess liver stiff gold standard way clinic
verifi nash liver biopsi key aim field develop non-invas test
nash nafld allow screen
exhibit diagnosi nash
standard care nash includ lifestyl chang better manag relat
metabol diseas diabet hyperlipidemia possibl bariatr surgeri
pharmacolog treatment exist nash creat larg opportun base
need
exhibit clinic endpoint nash
approxim million individu us estim progress nash
nash-rel cirrhosi model nash patient us
receiv treatment use younossi et al hepatolog templat
calcul proport nash patient fall categori nash without
fibrosi nash fibrosi nash compens cirrhosi nash
decompens cirrhosi nash portal hypertens
exhibit annual predict case nafld subcategori studi estim
nash patient fibrosi fb patient nash cirrhosi cr us
opportun nash differenti
develop oral small molecul thr-b agonist compound nash fibrosi
current trial show promis surrog top line data liver fat reduct
key catalyst biopsi data
investig nash compound target sever aspect multifactori diseas
fibrosi lipid inflamm insulin signal target thr-b receptor
primarili respons metabol action liver includ cholesterol-
tg-lower compound directli target lipid synthesi fxr
nv ppar gnft thr rational
correct lipid homeostasi target metabol storag triglycerid
inflammatori lipid speci reduc nash
exhibit categori moa nash
farnesoid receptor fxr transcript factor regul cholesterol alpha-
hydroxylas bile acid natur ligand fxr fxr play critic role bile
acid synthesi carbohydr lipid metabol regul insulin sensit
growth regener liver injuri bile acid circul liver
intestin back cycl call enterohepat circul fxr highli
express tissu particip bile acid metabol liver intestin
kidney high dietari cholesterol activ liver receptor shown
neg affect balanc storag oxid fatti acid
non-triglycerid metabolit diacylglycerol
lysophosphatidyl cholin drive lipotox injuri liver cell one critic fxr target
gene gut fibroblast growth secret growth factor
signal cell-surfac receptor tyrosin kinas fxr shown
involv liver cirrhosi activ hepat stellat cell hsc thought
mediat process liver fibrosi secret extracellular matrix protein
ultim lead scar liver tissu fxr activ also reduc hepat
express sterol regulatori element bind protein result reduc triglycerid
cholesterol content liver fxr also play critic role insulin sensit fxr
activ lower plasma glucos free fatti acid triglycerid total cholesterol
addit direct role fxr indirectli regul carbohydr lipid metabol
insulin sensit increas secret small intestin
exhibit moa fxr pathway nash
three type nuclear receptor peroxisom proliferator-activ receptor ppar
identifi ppar ppar ppar ppar mainli influenc fatti acid
metabol activ lower lipid level ppar mostli involv
regul adipogenesi energi balanc lipid biosynthesi ppar/
particip fatti acid oxid mostli skelet cardiac muscl also
regul blood glucos cholesterol level recogn ppar also
modul inflammatori respons regul cell divis associ liver
fibrogenesi tumorigenesi categori includ thiazolidendion tzd
genfit elafibranor cymabay seladelpar
exhibit moa ppar pathway nash
anti-inflammatori compound aim reduc amount inflamm liver
liver great regen abil compensatori growth howev sustain
sever liver injuri lead scenario gener apoptot cell outpac
bodi abil effect remov surround tissu build-up
apoptot materi lead cell death increas inflamm disease-
driven excess apoptosi result develop scar tissu fibrosi
lead tissu destruct eventu reduc capac organ function
normal conatu develop emricasan oral activ pan-caspas proteas
inhibitor design reduc activ human caspas enzym
mediat inflamm apoptosi allergan cenicriviroc cvc dual inhibitor
protein call play key role inflamm fibrosi
exhibit overview nash develop target thr-b correct lipid
target separ moa thyroid receptor thr normal lipid
synthesi thyroid hormon thyroxin
regul ldl-cholesterol triglycerid fatti liver insulin sensit hormon
also regul bodi weight exert physiolog effect bind specif
nuclear receptor thyroid hormon receptor thr wide
distribut throughout bodi two isoform major isoform
liver kidney thyroid predominantli express brain adipos
tissu anterior pituitari gland specif target thr- rather thr-
critic avoid cardiac side effect
major potenti differenti benefit thr- target favor effect
plasma cholesterol lipoprotein level multipl mechan includ
increas clearanc increas express high-dens
lipoprotein hdl uptak scaveng receptor class type bile
anoth thr- candid develop vike
thr- candid termin develop quatrx
karobio eprotirom due liver injuri ast alt level increas significantli
respect
companydrugmechanismstatusnashstatusdataintercept obetichol acid oca fxr regener fibrosi top-line earli revers cirrhosi initi bridg fibrosi compens stellar trial nash bridg fibrosi on-going stellar comp cirrhosi on-going top-line trial patient drug vs placebo achiev reduct fibrosi stage w/o worsen nash progress cirrhosi vs placebo progress cirrhosi vs placebo safeti genfit gnft elafibranor resolv trial on-going top-line novn tropifexor flight-fxr studi on-going enanta data safeti seladelparppar pbc onlyallegan former tobira cenicriviroc cvc immunomudul auror trial cur trial patient drug vs placebo achiv reduct fibrosi stage w/o worsen nash safeti galm glmd aramcholfatty-acid bile-acid nash ongoingfail meet endpoint hcv studi nafld top-lin ingelheimbi data expect -select top-line posit on-going complet april biopsysignific improv rel decreas liver fat mri patient treat compar placebo data mri surrogateth higher dose show statist signific reduct hepat steatosi non-invasive marker fibrosi vs placebo conatu cnat emricasancaspas cirrhosisposit data hcv nafld biomarkersvik vk -select data mild hypercholesterolemia madrig pharmaceut inc
exhibit mechan action
exhibit product attribut differenti potenti cv benefit
lower ldl-c multifacet impact sever nash factor
posit poc data nash fh
develop oral thr- agonist nash fh current trial
nash toplin decemb mri-pdff data data
present expect easl data expect full biopsi data
expect later
lower reduct marker nash-rel liver inflamm fibrosi drug
level similar lower ldl-c human clinic trial provid data
support advanc nash fh clinic trial chronic anim
toxicolog studi dog rat effect bone cartilag histolog seen
dose either speci
exhibit vivo show activ mani hallmark nash
improv liver triglycerid insulin toler alt histolog normal
hepat gene express mice high-fat diet hfd
clinic develop nash fh
on-going trial random double-blind placebo-control trial involv
subject biopsy-proven nash fibrosi fibrosi stage na
studi exclud cirrhot patient upon success screen subject
random receiv either match placebo
start dose patient mg day studi employ
adapt dose design wherebi blind fashion dose could adjust
small amount mg remain mg
patient base pharmacokinet analysi drug level perform patient
primari endpoint studi reduct liver fat week compar
baselin rel chang assess mri-pdff efficaci confirm end
trial week repeat mri-pdff convent liver biopsi examin
histolog evid resolut nash secondari endpoint includ
chang clinic relev biomark week improv fibrosi
least one stage worsen steatohepat safeti toler
week result expect biopsi data
exhibit trial nash patient fibrosi na posit top line
easl data biopsi read-out
exhibit baselin characterist trial nash patient fibrosi na
announc posit top line interim data decemb mri-pdff
data demonstr statist signific result primari endpoint
statist signific reduct hepat fat versu reduct placebo
measur magnet reson imag proton densiti fat fraction mri-
pdff week
also show reduct trend alt ast statist signific alt
ast reduct observ pre-specifi group rel higher mgl-
drug level patient drug-treat patient rel placebo patient
statist signific improv also seen multipl secondari endpoint
consid potenti clinic relev patient nash includ ldl-c
tg apob lipoprotein
exhibit top line interim result trial nash patient fibrosi
 na
easl present full data set overal data strong
marker point direct
exhibit week easl data show posit primari endpoint liver fat reduct
measur mri-pdff
exhibit improv mri-pdff seem constant across fibrosi stage
differ compound
exhibit surrog marker inflamm mri liver enzym indic potenti
reduct inflamm import na reduct nash resolut
exhibit surrog marker fibrosi show improv
well toler mostli mild advers event
moder number balanc placebo drug-treat
group advers effect safeti laboratori vital sign
paramet three seriou studi consid unrel mgl-
also develop
hypercholesterolemia hefh fh genet disord lead high level
cholesterol blood mg/dl typic hefh mg/dl
typic hofh increas cholesterol associ cv diseas fh typic
diagnos blood panel treat bile acid sequestr lipid-
lower agent statin etc hefh occur peopl
patient heterozyg
februari toplin hefh trial studi hefh patient
random placebo qd double-blind placebo-control fashion
week patient receiv drug top current cholesterol-low regimen
includ approxim take high-intens statin mg rosuvastatin
mg atorvastatin patient also take ezetimib studi
conduct europ clinic trial primari endpoint evalu
efficaci measur percent reduct ldl-c compar
placebo secondari endpoint includ safeti toler evalu efficaci
reduc varieti lipid paramet includ non-hdl-c apob tg
lp apoa/b lipoprotein particl
data show statist signific reduct ldl-c compar
placebo primari endpoint phase clinic trial hefh patient
maxim statin therapi ldl-c lower compar
placebo pre-specified group patient toler high-intens statin dose
statist signific result also achiev compar placebo
multipl secondari endpoint includ reduct triglycerid apolipoprotein
 apob lipoprotein highli atherogen lipid particl commonli
elev hefh patient
well toler trial compar placebo mostli mild
moder balanc drug-treat placebo unrel
placebo drug-treat
exhibit trial hefh patient posit top line
exhibit trial hefh patient posit top line signific reduct ldl-c
date complet seri clinic studi preclin
glp toxicolog studi drug manufactur studi support clinic
develop includ api manufactur drug product develop studi drug
metabol studi acut subchron chronic anim toxicolog studi
safeti pharmacolog toxicolog studi
complet studi total subject evalu safeti toler
pharmacokinet pharmacodynam effect studi includ
random placebo-control double-blind singl multiple-dos escal
studi well drug-interact studi healthi volunt illustr
exhibit daili dose rang mg show highli
statist signific reduct rel placebo ldl-c rang
non-hdl-c rang apob rang
statist trend reduct tg rang
near maxim lipid effect observ dose mg once-
daili well toler dose dose-rel advers event
liver enzym electrocardiographi vital-sign chang highest dose
mg revers reduct level precursor hormon
free significantli differ placebo may
explain increas liver metabol free chang thyrotropin
pituitari hormon regul level product thyroid hormon thyroid
gland evid central thyroid axi dysfunct dose mgl-
exhibit mad result
put efficaci perspect
see outcom mri-pdff readout final biopsi
readout like posit point na decreas base trial nash
expect trend statist signific nash resolut fibrosi stage
compar data fxr trial oca ppar trial elafibranor
centaur trial cvc
gener agn trial centaur sever popul term na
score fibrosi stage gnft less sever popul golden trial
mdgl enrol popul interim analysi compar
gnft popul base na score vs fibrosi stage patient diabet
key differ includ patient
gener data nash trial show
nash sever stratif factor compound perform better
advanc patient gnft post hoc analysi vs initi use
stronger hr agn centaur trial
diabet stratif factor oca perform better patient diabet
term na improv diabet patient vs without
cvc perform better term fibrosi improv non-diabet
patient princip driven lower placebo respons non-diabet patient
fibrosi improv gener observ patient improv
fibrosi golden trial gnft signific patient
patient two trial enrol patient
show improv fibrosi score point
exhibit recent trial nash
view popul similar gnft golden trial
less sever popul despit high averag na score
closest golden averag flint centaur
key differ golden mdgl studi enrol patient
largest fraction patient compar trial
time treatment mdgl trial shortest week vs
week nash trial pioglitazon studi shorter time
show signal believ week appropri
sinc nash sever stratif factor patient higher sever
respond better least golden centaur rais bar
manag state potenti trial would larger
popul patient
histolog outcom base mri-pdff improv believ
histolog show statist signific point na decreas believ
histolog show trend fibrosi nash resolut result
icptgnftfagnmdglflint easl present inclus na greater least compon na score steatosi score balloon degener score lobular inflamm score diagnosi noncirrhot nash least compon nashistolog diagnosi noncirrhot nash least score follow na componentscomparisonoca daili vs placeboelafibranor daili vs placebocenicriviroc vs placebo daili crossov arm placebo drug primari week weeksprimari worsen fibrosisworsen fibrosi nash crn fibrosi stage worsen fibrosi year baselin hepat fat fraction assess mri-pdff week stage patient stage decreas nafld activ score na least pointsprogress stage patient stage decreas nafld activ score na least point point improv categori year endpointsresolut nash diagnosisresolut nash diagnosi score compon complet resolut steatohepat concurr worsen fibrosi stage year reduct na score week chang scorestag fibrosisimprov fibrosi least stage nash crn system worsen steatohepat year non-alcohol steatohepat nash balloon inflamm week nafld activ score chang scorena scorechang histolog fibrosi stage year fibrosi least stage worsen steatohepat week alt/ast biomarkersstag steatosishistolog improv na concurr worsen fibrosi stage year baselin hepat fat fraction week alt/ast biomarkerschang alt/ast biomarkersbaselinebmi mg/mlhdl-c mg/dltriglycerid drug placebo drug stage drug activ score na endpoint patient vs vs vs placebo chang absolut vs absolut placebo vs mod definit week vs fibrosi patient liver fat reduct vs placeboresolut nash vs vs sub-populationfibrosi patient vs stage improv vs placebo year stage improv vs placebofibrosi chang vs chang vs non-respond nafld activ score vs vs sub-populationweigth loss weight loss compar placebotr weight loss lipid reductionldl-c triglycerid cfbrel placebo ng/mlelfapprox vs placeboalt astalt ast decreas rel mean baselin drug placebo madrig pharmaceut inc
fibrosi golden show fibrosi improv princip
patient enrol even fewer
patient enrol believ allow trial show
signific reduct fibrosi separ show
point mean decreas fibrosi score uncontrol week
base posit mri-pdff score larger rel decreas
score uncontrol data importantli
show patient improv remain constant
progress term fibrosi improv patient
improv impli respond
mean decreas na underscor import
sever patient trial show improv fibrosi
nash resolut nash resolut princip achiev
reduct inflamm balloon due score system
less impact steatosi show strong reduct liver fat
via mri-pdff potenti reduct inflamm via
alt ast marker howev due lower na baselin score
compar nash trial lower patient number believ
trial power show signific portion nash resolut
show uncontrol small trial greater rel
reduct alt data patient achiev nash
resolut consequ expect trend nash resolut
diabet also lowest mdgl patient cohort impact diabet
mix oca perform better patient diabet term na
improv cvc perform better term fibrosi improv
gild mozart trial ezetimib mri-pdff week show lower
respons rate via mri-pdff patient achiev reduct liver
fat mri-pdff still show signific histolog endpoint
week posit indic on-going trial
overal see trial well design enrol base fact improv
na score stronger sever patient improv na
appropri agent modifi lipid synthesi mri-pdff alreadi shown
improv liver fat key read-out biopsi data week may
base less sever popul compar flint centaur line
golden albeit without patient believ trial like deliv improv
histolog base reduct na base fact golden achiev
improv fibrosi improv na score post hoc analysi
patient mri-pdff shown good indic
outcom howev also believ trial show statist signific
reduct fibrosi nash resolut due small size enrol popul
nash resolut improv fibrosi demonstr trial
dose could optim base biomark similar statin could
enrol sever nash popul see na improv posit
outcom sinc nash resolut fibrosi improv still need
demonstr subsequ trial development risk remain
exhibit mozart trial ezetimib mri-pdff week show lower
respons rate via mri-pdff histolog endpoint show signific mdgl
mri-pdff correl histolog
measur time
key question posit interim data mri-pdff reliabl predictor
improv histolog improv na score point see na
score improv readout key readout nash resolut
announc posit top line interim data decemb mri-pdff
data demonstr statist signific result primari endpoint
statist signific reduct hepat fat vs reduct placebo
measur magnet reson imag proton densiti fat fraction mri-
pdff week
point two studi demonstr correl mri-pdff measur
histolog
mri-pdff correl histolog grade hepat steatosi rel
decreas mri-pdff associ histolog respons
nash point na reduct patel et al howev weak point
studi differ baselin characterist term diabet
tg na score respond non-respond
mri-pdff correl reduct na score gild trial week
believ correl non-invas test mri-pdff histolog
suffici establish expect improv na score on-going trial
outstand issu show mri-pdff noisi
studi use mri-pdff test predictor improv
histolog later time point
mri-pdff chang liver fat correl well steatosi much
exhibit mri-pdff substudi mozart trial ezetimib histolog respond
na improv point show reduct liver fat vs increas non-
respond baselin characterist differ respond non-respond
exhibit trial mri-pdff week mri-pdff biopsi week
patient popul similar mdgl trial popul
middleton et al intern workshop nash biomark
exhibit trial mri-pdff week correl strongli improv
middleton et al intern workshop nash biomark
exhibit trial mri-pdff week correl steatosi good
good inflamm
observ thr- peer
vike therapeut madrig develop select thr- agonist nash
see posit signal moa earli compar outcom
look conserv result data show moa show clinic efficaci
lower ldl-c tg trial see support th-
exhibit studi day thr- agonist show reduct ldl-c
tg
safeti may superior termin
safeti concern thr- agonist could includ reduct level
precursor hormon free consequ disrupt signal axi
possibl cv effect bone loss due thr- target liver toxic thr-
agonist compound discontinu clinic develop quatrx
karobio eprotirom due liver injuri ast alt level increas
significantli respect
see safeti issu valid base data
thr- select agonist key differenti discontinu
eprotirom select thr- eprotirom
acid modestli
trb-select thyromimet highli thr- select agonist
thr- jakobsson et al drug
trial highest dose mg revers reduct
level precursor hormon free significantli differ
placebo may explain increas liver metabol free
chang thyrotropin pituitari hormon regul level
product thyroid hormon thyroid gland evid central
thyroid axi dysfunct dose
vivo studi show littl alpha-mhc mrna marker myocyt injuri bone
key focu data present continu safeti especi alt ast bone
exhibit thr- compound clinic develop
exhibit inact vivo heart studi
exhibit improv safeti profil compar
estim least nash patient unit state
preval model nash without fibrosi nash
fibrosi nash compens cirrhosi also
portal hypertens nash decompens cirrhosi base
research approxim nash fibrosi patient popul studi
diagnosi undergo form treatment project
potenti approv assum pay tier
single-digit royalti roch model initi net price
annual us us price eu japan respect
base drug use larg popul model potenti
penetr nash patient expect peak sale reach
nash un-risk-adjust us row assum probabl
success model us row risk-adjust peak revenu
nash
fh set model preval probable/definit hefh
rate model preval hofh built model
preval assum chronic use three popul sever hefh patient
hefh popul hefh patient ldl-c treatment goal hefh
patient hofh patient model potenti penetr hefh
reach ldl-c goal high-dos statin sever hefh hofh
patient estim treatment cost us forecast un-risk-
adjust sale fh us row assum probabl
success peak risk-adjust sale us row
exhibit project revenu un-risk adjust adjust nash
fh probabl success
exhibit project revenu un-risk adjust adjust nash
fh probabl success peak nash key indic
expect licens composit matter patent expir
unit state intern without extens co-own patent
pend patent applic cover compani particular solid form dosag
method manufactur use treat variou indic expect
expir model loss ip
risk un-adjust sale per nash nash hefh hefh risk -adjust sale per nash nash hefh hefh un-adjust us nash nash hefh hefh adjust us nash nash hefh hefh rowpositionnameceo chairmanpaul friedman cmo evp founderrebecca taub svp cfomarc schneebaum madrig inc
paul friedman chairman chief execut offic
paul friedman serv chairman board director chief
execut offic sinc juli dr friedman serv member synta
pharmaceut corp board director march april dr
friedman serv chief execut offic director incyt corpor
novemb retir januari serv
presid research develop dupont-merck compani
presid dupont pharmaceut research laboratori
wholli own subsidiari dupont compani serv
senior vice presid merck research laboratori prior tenur merck
dupont dr friedman associ professor medicin pharmacolog
harvard medic school dr friedman diplomat american board intern
medicin member american societi clinic investig dr friedman
current sit board director cerulean pharma inc publicli trade
incyt corpor publicli trade pharmaceut compani gliknik inc
previous serv board director auxilium pharmaceut inc publicli
trade pharmaceut compani durata therapeut inc publicli trade
pharmaceut compani dr friedman receiv biolog princeton
univers harvard medic school
rebecca taub director founder chief medic offic execut vice
rebecca taub serv chief medic offic execut vice presid
research develop member madrig board director sinc juli
previous dr taub serv chief execut offic member
board director privat held inc incept
merger synta pharmaceut corp prior join madrig dr taub serv
senior vice presid research develop
vice presid research metabol diseas hoffmann-la roch
posit dr taub oversaw clinic develop drug
discoveri program cardiovascular metabol diseas includ conduct
seri phase ii proof-of-conduct clinic trial dr taub led drug discoveri
includ target identif lead optim advanc preclin candid
clinic develop dr taub work bristol-my
squibb co dupont pharmaceut compani varieti posit includ
execut director metabol diseas research becom
pharmaceut execut dr taub tenur professor genet medicin
univers pennsylvania dr taub author research articl
join faculti univers pennsylvania dr taub serv
assist professor joslin diabet center harvard medic school harvard
univers associ investig howard hugh medic institut dr
taub receiv yale univers school medicin yale
marc schneebaum senior vice presid chief offic
marc schneebaum serv senior vice presid chief offic
sinc juli previous mr schneebaum serv senior vice presid chief
financi offic synta pharmaceut corp decemb juli mr
schneebaum year experi biotechnolog healthcar
sector prior join synta mr schneebaum serv consult healthcar
industri mr schneebaum serv presid chief execut
offic director predict bioscienc inc commercial-stag cancer
diagnost compani serv presid chief execut
offic director sensor medicin scienc inc emerg medic
technolog compani serv senior vice presid financ
busi develop administr chief offic genet
therapi inc biotechnolog compani acquir sandoz/novarti
mr schneebaum vice presid brown son incorpor
invest bank firm part deutsch bank particip varieti
financ strateg assign mr schneebaum began career account
audit group kpmg llp advanc senior manag manag
consult group mr schneebaum serv director genvec inc publicli
trade biopharmaceut compani sinc mr schneebaum earn
busi administr account univers maryland
expect peak sale nash reach billion ww us un-
risk-adjust market share fibrot patient initi annual
price us assum probabl success nash estim
ww fh opportun reach un-risk adjust sale peak initi annual
price us line nash assum probabl success fh
project potenti approv nash fh
exhibit probability-adjust sale forecast
risk un-adjust us salesrisk-adjust us salestot risk un-adjust sale per nash nash hefh hefh risk -adjust sale per nash nash hefh hefh un-adjust us nash nash hefh hefh adjust us nash nash hefh hefh row madrig pharmaceut inc
exhibit sale forecast
valu use dcf analysi assum wacc
residu growth rate due loss ip protect
ep respect expect growth ep
appear well financ cash balanc
exhibit dcf valuat
risk un-adjust revenu nash hefh us nash hefh row nash outgo sale adjust revenu adjustmentsprob nash nash hefh risk-adjust us nash hefh row nash yeartermin valu growth valu valu per sharetermin valu growth rate perform
exhibit dcf sensit analysi around probabl success asset
valu per shareprob success nashprob success fh madrig pharmaceut inc
exhibit incom statement forecast
except per share data fy probabl adj product revenues- nash- hefh- revenu milestones- total revenues- goods- cogs- outgo royalti outgoingmileston gross profit- oper expensesresearch develop adjust research develop share-bas compens total share-bas gener administr adjust sell gener administr share-bas compens total share-bas share-bas compens exclud non- op other- total oper expens oper interest dividend interest incom expens incom comprehens incom loss comprehens incom incom tax expens benefit tax basic share outstand share outstand ep ep oppenheim co estim compani data perform
exhibit balanc sheet forecast
fy asset cash market prepaid expens current account receivable- inventories- defer tax assets- total current fix asset defer tax assets- non-curr assets- total liabilitiescurr liabil account accru defer revenue- total current long-term portion warrant liability- long-term portion defer revenue- long-term debt- total total stockhold total liabil sourc oppenheim co compani report inc
exhibit statement forecast
fy incom adjustmentsdepreci stock compens amort premium market securities- loss sale assets- accru interest includ convert note other- chang oper asset liabilitiesaccount inventories- prepaid expens current account payabl accru accru interest relat assets- flow sale purchas avail sale purchas fix flow proce issuanc common proceed exercis option warrants- proce issuanc convert princip payment promissori note- flow effect fx- net increas decreas equival equival sourc oppenheim co compani report
discount analysi except per-shar data mn except per-shar data revenu growth chang work work capit valu growth valu stock oppenheim valu per sharetermin valu growth rateequ valu per shareprob success nashprob success fh inc
risk un-adjust revenu nash hefh us nash hefh row nash outgo sale adjust revenu adjustmentsprob nash nash hefh risk-adjust us nash hefh row nash oppenheim co estim perform
probabl success
probabl success
collabor revenu mileston
good
outgo royalti
outgoingmileston
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op ex
interest dividend incom
stock price compani mention report
